Antibe Therapeutics Inc
Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSA… Read more
Antibe Therapeutics Inc (ATBPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: -0.148x
Based on the latest financial reports, Antibe Therapeutics Inc (ATBPF) has a cash flow conversion efficiency ratio of -0.148x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.85 Million) by net assets ($25.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Antibe Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2023)
This chart illustrates how Antibe Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Antibe Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Antibe Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mega Manunggal Property TBK PT
JK:MMLP
|
0.000x |
|
Arcure SA
PA:ALCUR
|
0.207x |
|
AMJ Global Technology
PINK:AMJT
|
0.014x |
|
FuelPositive Corp
OTCQB:NHHHF
|
0.001x |
|
Apexindo Pratama Duta Tbk
JK:APEX
|
0.129x |
|
Vince Holding Corp. Common Stock
NASDAQ:VNCE
|
-0.095x |
|
M K Land Holdings Bhd
KLSE:8893
|
0.000x |
|
GéoMégA Resources Inc
OTCQB:GOMRF
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Antibe Therapeutics Inc (2012–2023)
The table below shows the annual cash flow conversion efficiency of Antibe Therapeutics Inc from 2012 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-03-31 | $40.17 Million | $-16.30 Million | -0.406x | -36.35% |
| 2022-03-31 | $56.83 Million | $-16.92 Million | -0.298x | -14151.73% |
| 2021-03-31 | $50.26 Million | $-105.00K | -0.002x | +99.93% |
| 2020-03-31 | $3.78 Million | $-11.94 Million | -3.158x | -233.06% |
| 2019-03-31 | $7.44 Million | $-7.06 Million | -0.948x | -17.24% |
| 2018-03-31 | $7.98 Million | $-6.45 Million | -0.809x | +16.44% |
| 2017-03-31 | $3.55 Million | $-3.44 Million | -0.968x | -64.53% |
| 2016-03-31 | $4.71 Million | $-2.77 Million | -0.588x | +94.77% |
| 2015-03-31 | $337.19K | $-3.80 Million | -11.256x | -1174.19% |
| 2014-03-31 | $3.32 Million | $-2.93 Million | -0.883x | -284.80% |
| 2013-03-31 | $-1.01 Million | $-481.32K | 0.478x | -52.13% |
| 2012-03-31 | $-225.76K | $-225.45K | 0.999x | -- |